Liquidia Corp (LQDA)
NASDAQ NMS - GLOBAL MARKET · Drug Manufacturers - Specialty & Generic
$86.82+2.40 (+2.84%)Quote refreshed
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
$7.72B
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
No company overview is available for Liquidia Corp yet.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →TAK#1
Takeda Pharmaceutical Company Limited
$57.78B-1.07%
ZTS#2
Zoetis Inc.
$50.46B+0.20%
HLN#3
Haleon plc
$43.61B+0.40%
TEVA#4
Teva Pharmaceutical Industries Limited
$36.05B+1.44%
UTHR#5
United Therapeutics Corporation
$25.19B-1.19%
VTRS#6
Viatris Inc.
$15.85B+0.29%
RGC#7
Regencell Bioscience Holdings Limited
$13.93B-2.46%
NBIX#8
Neurocrine Biosciences, Inc.
$13.21B-1.13%
ELAN#9
Elanco Animal Health Incorporated
$11.66B-0.59%
RDY#10
Dr. Reddy's Laboratories Limited
$10.92B+0.15%
Recent press releases
Liquidia Corp has not issued a press release in this window.
SEC filings
All filings →Liquidia Corp has not filed an SEC document in this window.
Insider trades
All insider trades →Liquidia Corp has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
17,221,676 sh+101.0%
Caligan Partners LP$280.0M
8,118,892 sh0.0%
BlackRock, Inc.$189.3M
5,488,363 sh+5.0%
1,927,420 sh+151.6%
VANGUARD GROUP INC$138.4M
4,013,888 sh+1.3%
4,207,449 sh-3.0%
BIOIMPACT CAPITAL LLC$48.3M
1,400,869 sh+600.4%
1,236,586 sh● NEW
People at Liquidia Corp
All people →Quarterly financials
Full financials →Revenue trend
03/25
$3.1M
NI -$38.4M
06/25
$6.5M
NI -$41.6M
09/25
$54.3M
NI -$3.5M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.04
Prior: $-0.49
Revenue sparkline